UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin

Anti-cancer drugs, 2012-02, Vol.23 (2), p.173-184

2012

Volltextzugriff (PDF)

ADR1-Mediated Transcriptional Activation Requires the Presence of an Intact TFIID Complex

Molecular and Cellular Biology, 1998-10, Vol.18 (10), p.5861-5867

1998

Volltextzugriff (PDF)

Histone-like TAFs Are Essential for Transcription In Vivo

Molecular cell, 1998-11, Vol.2 (5), p.663-673

1998

Volltextzugriff (PDF)

Phase IB trial of EMD 273066 (huKS-IL2) with cyclophosphamide in patients with EpCAM-positive advanced solid tumors

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.2556-2556

2011

Volltextzugriff (PDF)

A phase I study of palifosfamide in combination with doxorubicin: Safety and preliminary efficacy

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.10577-10577

2009

Volltextzugriff (PDF)

Evaluation of indibulin, a novel tubulin targeting-agent, in combination with capecitabine, with mathematically optimized dose scheduling

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.2538-2538

2009

Volltextzugriff (PDF)

A novel arsenical has antitumor activity toward As O -resistant and MRP1 ABCC1-overexpressing cell lines

Leukemia, 2009-02, Vol.23 (2), p.431-431

2009

Volltextzugriff (PDF)

A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines

Leukemia, 2009-02, Vol.23 (2), p.431

2009

Volltextzugriff (PDF)

Novel organic arsenic molecule darinaparsin: Development of IV and oral forms

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.8501-8501

2009

Volltextzugriff (PDF)

A novel arsenical has antitumor activity toward As sub(2)O sub(3)-resistant and MRP1/ABCC1-overexpressing cell lines

Leukemia, 2008-10, Vol.22 (10), p.1853-1863

2008

Volltextzugriff (PDF)

Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models

Nature medicine, 2010-07, Vol.16 (7), p.788-792

2010

Volltextzugriff (PDF)

A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors

Clinical cancer research, 2019-01, Vol.25 (2), p.496-505

2019

Volltextzugriff (PDF)

Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)-Rearrangement (R) or Nucleophosmin 1 (NPM1) Mutation (m)

Blood, 2022-11, Vol.140 (Supplement 1), p.3371-3372

2022

Volltextzugriff (PDF)

A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease

Molecular genetics and metabolism, 2007-07, Vol.91 (3), p.259-267

2007

Volltextzugriff (PDF)

A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors

BMC cancer, 2013-01, Vol.13 (1), p.20-20, Article 20

2013

Volltextzugriff (PDF)

Growth Indices of Siberian Pine of Different Geographical Origin Grafted on a Scots Pine Rootstock

Izvestiâ vysših učebnyh zavedenij. Lesnoj žurnal, 2020-04 (2), p.9-19

2020

Volltextzugriff (PDF)

Phase 1/2 study of veliparib (V) combined with carboplatin (Cb) and etoposide (E) in patients (pts) with extensive-stage disease (ED) small cell lung cancer (SCLC) and other solid tumors: Phase 1 results

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.8530-8530

2017

Volltextzugriff (PDF)

Nuclear-cytoplasmic incompatibility in cybrids possessing an Atropa belladonna nuclear genome and a Nicotiana tabacum plastome

Biopolimery i kletka, 1990-09, Vol.6 (5), p.91-98

1990

Volltextzugriff (PDF)

26 – 42 von 42

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(42)

Sprache

Englisch
(42)
Russisch
(1)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin

ADR1-Mediated Transcriptional Activation Requires the Presence of an Intact TFIID Complex

Histone-like TAFs Are Essential for Transcription In Vivo

Phase IB trial of EMD 273066 (huKS-IL2) with cyclophosphamide in patients with EpCAM-positive advanced solid tumors

A phase I study of palifosfamide in combination with doxorubicin: Safety and preliminary efficacy

Evaluation of indibulin, a novel tubulin targeting-agent, in combination with capecitabine, with mathematically optimized dose scheduling

A novel arsenical has antitumor activity toward As O -resistant and MRP1 ABCC1-overexpressing cell lines

A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines

Novel organic arsenic molecule darinaparsin: Development of IV and oral forms

A novel arsenical has antitumor activity toward As sub(2)O sub(3)-resistant and MRP1/ABCC1-overexpressing cell lines

Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models

A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors

Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)-Rearrangement (R) or Nucleophosmin 1 (NPM1) Mutation (m)

A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease

A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors

Growth Indices of Siberian Pine of Different Geographical Origin Grafted on a Scots Pine Rootstock

Phase 1/2 study of veliparib (V) combined with carboplatin (Cb) and etoposide (E) in patients (pts) with extensive-stage disease (ED) small cell lung cancer (SCLC) and other solid tumors: Phase 1 results

Nuclear-cytoplasmic incompatibility in cybrids possessing an Atropa belladonna nuclear genome and a Nicotiana tabacum plastome

Suchergebnisse filtern